Sangamo Biosciences Reports Presentation of Clinical Data from Alzheimer's Program

Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease (AD). This novel product was developed by Ceregene, Inc., which was recently acquired by Sangamo.